Clin2
NCT07216027Possibly a fitRecruiting

A study of a new eczema medicine for adults

Atopic DermatitisEczema, Atopic

Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.

This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
165 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • You are between 18 and 64 years old.
  • You have had eczema for at least 6 months, and a doctor confirmed it with photos.
  • Your eczema covers at least 10% of your body (but not more than 60%) and is moderate to severe based on doctor checks and itching scores.
  • You do not have a prescription eczema medicine that works for you.
  • Your body mass index (BMI) is between 18 and 38, and you weigh more than 106 pounds.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06564389Recruiting· Phase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients

This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.

Anaheim, California
NCT06397911Recruiting· Phase 2
Testing FB825 for moderate to severe eczema

This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.

Fountain Valley, California
NCT07643766Recruiting· Phase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis

This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.

Encinitas, California
NCT06808477Recruiting· Phase 1
BBT001 for moderate to severe eczema

This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.

Irvine, California
NCT07037901Recruiting· Phase 2
Testing IMG-007 for moderate-to-severe eczema

This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.

Lancaster, California
NCT05995964Recruiting· Phase 2
Study of two new medicines for eczema

This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.

Birmingham, Alabama

Hear when a new Atopic Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.